U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 26 results

Status:
US Approved Rx (2016)
First approved in 1995

Class (Stereo):
CHEMICAL (ACHIRAL)



Riluzole, a member of the benzothiazole class, is indicated for the treatment of patients with amyotrophic lateral sclerosis. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

BMS-191011, an opener of the cloned large-conductance, Ca2+-activated potassium (maxi-K) channel, demonstrated efficacy in in vivo stroke models, which led to its nomination as a candidate for clinical evaluation. Its maxi-K channel opening propertie...
Pimaric acid is a carboxylic acid from the resin acid group. It is a BK-channel opener and inhibits TNF-alpha induced signaling by downregulating NF-kB and AP-1.
Paxilline is a toxic, tremorgenic indole alkaloid produced by Penicillium paxilli. Paxilline is inhibitor of BK channels, and is widely used as a tool compound to test role of BK channels in various conditions. Paxilline demonstrated therapeutic bene...
Status:
US Previously Marketed
First approved in 1947

Class (Stereo):
CHEMICAL (ACHIRAL)



Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. Tetraethylammonium blocks of apamin-sensitive and insensitive Ca2(+)-activated K+ channels. It is a weak agonist of the nicotinic receptor. Tetraethylammo...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (RACEMIC)



Trimebutine [3,4,5-trimethoxybenzoic acid 2-(dimethylamino)-2-phenylbutylester] is a noncompetitive spasmolytic agent. The actions of trimebutine on the gastrointestinal tract are mediated via (i) an agonist effect on peripheral mu, kappa and delta o...
Status:
US Approved Rx (2016)
First approved in 1995

Class (Stereo):
CHEMICAL (ACHIRAL)



Riluzole, a member of the benzothiazole class, is indicated for the treatment of patients with amyotrophic lateral sclerosis. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on...
Status:
US Approved Rx (2016)
First approved in 1995

Class (Stereo):
CHEMICAL (ACHIRAL)



Riluzole, a member of the benzothiazole class, is indicated for the treatment of patients with amyotrophic lateral sclerosis. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on...
Status:
US Previously Marketed
First approved in 1947

Class (Stereo):
CHEMICAL (ACHIRAL)



Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. Tetraethylammonium blocks of apamin-sensitive and insensitive Ca2(+)-activated K+ channels. It is a weak agonist of the nicotinic receptor. Tetraethylammo...
Status:
US Previously Marketed
First approved in 1947

Class (Stereo):
CHEMICAL (ACHIRAL)



Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. Tetraethylammonium blocks of apamin-sensitive and insensitive Ca2(+)-activated K+ channels. It is a weak agonist of the nicotinic receptor. Tetraethylammo...